Form 4: Arcturus Therapeutics CEO Acquires 196,000 Stock Options

Arcturus Therapeutics CEO, Joseph E. Payne, was granted 196,000 stock options on December 16, 2024, according to a recent SEC filing.

Summary

• Joseph E. Payne, the President and CEO of Arcturus Therapeutics Holdings Inc., was granted 196,000 employee stock options on December 16, 2024.
• The options have an exercise price of $16.24 per share.
• These options vest 25% on December 16, 2025, and the remaining 75% vest in equal monthly increments over the following 36 months.
• The options expire on December 16, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• Vesting schedules, such as the one described, are typical to ensure long-term commitment from executives.
• The exercise price of $16.24 is relevant to the current market price of the stock, which is not mentioned in the document.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the CEO's interests with the company's long-term success.
• The vesting schedule encourages the CEO to remain with the company for the long term.

Key Dates

Keywords

stock options, executive compensation, insider trading, SEC Form 4, Arcturus Therapeutics, Joseph E. Payne